Tesamorelin

For research purposes only, this product is not intended for human consumption, diagnosis, or treatment. It has not been approved by the FDA or MHRA. Sales are limited to qualified researchers and institutions, and misuse could lead to account termination or legal consequences.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), designed to stimulate the pituitary gland to release growth hormone. It has been modified with an N-terminal hexenoyl group to enhance its stability and resistance to enzymatic degradation.
Mechanism of Action: Tesamorelin binds to GHRH receptors in the anterior pituitary, stimulating the release of growth hormone. This promotes the production of insulin-like growth factor-1 (IGF-1), which plays a key role in regulating metabolism, reducing visceral fat, and supporting tissue repair.
Key References
• Falutz J, et al. “Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients with Lipodystrophy.” New England Journal of Medicine, 2010.
• Guaraldi G, et al. “Tesamorelin for the Treatment of HIV-Associated Lipodystrophy.” Current Opinion in HIV and AIDS, 2011.